Pioneers in Immunoregulatory Drug Discovery and Development
We develop novel immunoregulatory therapeutics for patients with autoimmune diseases, starting with ulcerative colitis and Crohn’s disease.
Our Mission
We are a late-clinical-stage precision immunology biopharmaceutical company focused on the development of best-in-class biomarker-driven immunoregulatory therapeutics. Our lead clinical candidate, omilancor, is a Phase 3-ready, first-in-class, oral, gut-restricted LANCL2 agonist for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD).
Our management team has significant experience in development of immunoregulatory drugs and a proven track record of effectively accelerating drug candidates into and through late-stage clinical development. We are on a mission to develop safer and more effective therapeutics that address the unmet needs of patients with autoimmune diseases.
Press and Articles from NImmune
Oral Omilancor Treatment Ameliorates Clostridioides difficile Infection During IBD Through Novel Immunoregulatory Mechanisms Mediated by LANCL2 Activation
Clostridioides difficile infection (CDI) is an opportunistic infection of the gastrointestinal tract, commonly associated with antibiotic administration, that afflicts almost 500 000 people yearly only in the United States. CDI incidence and recurrence is...
Scientists behind LANCL2 target launch with phase III-ready drug
Many of the available treatments for the autoimmune conditions ulcerative colitis (UC) and Crohn’s disease come with drawbacks such as safety issues or inconvenient dosing regimens. Describing itself as a biomarker-driven immunoregulatory therapeutics company,...
NImmune Biopharma Provides Update on Omilancor Clinical Development Programs in Ulcerative Colitis and Crohn’s Disease
Approvable population of ulcerative colitis (UC) patients for upcoming Phase 3 trials agreed upon with the U.S. Food and Drug Administration (FDA) Analysis of Phase 2 data using approvable UC patient population for Phase 3 demonstrated statistical significance in...
NImmune Leadership Team
A highly experienced and talented team with deep knowledge of LANCL therapeutics and a proven track record of biotech industry success.
Product Candidates
NImmune’s clinical development pipeline includes best-in-class biomarker-driven immunoregulatory therapeutics for autoimmune diseases with multiple catalyst milestones. Lead clinical candidate omilancor, a Phase 3-ready immunoregulatory therapeutic targeting LANCL2, is an oral, once-daily, gut-restricted, first-in-class therapeutic for Ulcerative Colitis and Crohn’s disease with registration-directed pivotal clinical trials planned for 2023 with data readout in 12-18 months.
Learn more about the omilancor story, LANCL2 mechanism of action, and the market opportunity we seek to address.
Contact Us
If you would like to know more about our research, please fill out the form below.